Psychiatric neuroscientist (with capital Ψ, lowercase n)
| Causal mapper of @braincircuits.bsky.social
| Neuropsychiatrist
| Asst Prof @harvard.edu
| husband, father of a pure-bred Bengal cat and a 37.5% Bengal human
Shan Siddiqi
Loading...
So perhaps the best marker of "target engagement" is when you get target-specific clinical improvement, not just when you see biomarker changes in a circuit.
That'd be analogous to most diseases, where the treatment target isn't usually detected the same way as the biomarker of treatment response.
The pre-specified primary outcome was negative: TMS-induced rsFC changes were not clearly target-specific and did not track clinical improvement.
But baseline rsFC was informative. TMS site rsFC to the targeted circuit did predict clinical outcomes.
#TWiNPP
From Baldi et al., baseline network alignment may be a useful biomarker for optimizing TMS outcomes in depression and anxiety / @shansiddiqi.bsky.social
www.nature.com/articles/s41...
I always assumed that brain function had to line up with cytoarchitectonics.
It turns out I was wrong.
Human cortex, especially PFC, is tiled by chains of functional patches that subdivide and interlink architectonic areas into parallel processing streams.
www.biorxiv.org/content/10.6...
Adding to the mountain of literature on baseline TMS site connectivity predicting clinical outcomes in a target-specific manner, while change in connectivity has not been reproducibly linked to specific targets or specific clinical outcomes.
